WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “
Company” or “
WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has been conditionally awarded a grant of $6,730,036 (20,394,049.68 PLN) from the Polish National Center for Research and Development (“
NCRD”), for the development of Annamycin, the Company’s drug candidate used in the treatment of Acute Myeloid Leukemia (“
AML”).
Annamycin is a “next generation” anthracycline, that has been shown to be less cardiotoxic compared to other anthracycline, such as doxorubicin, and to avoid multidrug resistance, so the use of Annamycin may not face the same dose limitations imposed on doxorubicin. The project entitled: “A novel approach to the therapy of acute myeloid leukemia (AML)” will be co-financed by the European Union, from the European Regional Development Fund, under the Smart Growth Operational Program 2014-2020. The funds will be used on the continued development of An
Share:
WPD Pharmaceuticals Inc. (CSE:WBIO)(FSE: 8SV1) (the
Company or
WPD ) a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10
th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021.
During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: New approach to glioblastoma treatment addressing the critical unmet medical need , granted by National Research and Development Center (
NRDC ) and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020.
Share this article
HOUSTON, Feb. 18, 2021 /PRNewswire/ WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ( WPD ) and
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ( CNS or the Company ), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD Pharmaceuticals received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Muliforme (GBM) under the WPD-201 Clinical Trial Protocol. CNS Pharmaceuticals has received study level Central IRB Approval from the Central IRB for the CNS-201 Clinical Trial Protocol.